Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Tolerability of an Ancient Grain in Patients With Non-Celiac Wheat Sensitivity

A legfontosabb adatok

Ki végzi
University of Palermo
Hol
Olaszország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
68 fő, tervezett
Kezdés
2024. febr. 1.
Várható befejezés
2026. nov. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • Administration of Triticum Monococcum flour
  • Administration of Triticum Aestivum flour
A regiszteradat frissítve
2026. január 12.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults already diagnosed with non-celiac wheat sensitivity (NCWS) who follow a strict wheat-free diet. They will try two kinds of wheat flour, one ancient and one modern.

Életkor
>18 and <65 years
Nem
All sexes can join.
A betegség stádiuma
Non-celiac wheat sensitivity diagnosed by international criteria, including a double-blind placebo-controlled wheat challenge. No celiac disease and no wheat allergy.
Korábbi kezelés
People must be on a strict wheat-free diet. People who cut out gluten or wheat on their own and refuse to eat it again for testing cannot join.
Biomarker vagy leletérték
Negative IgA and IgG anti-DGP, anti-tTG and EMA blood tests. No intestinal villous atrophy (damage to the gut lining) in people carrying DQ2 and/or DQ8. Negative wheat allergy tests (prick test and/or IgE to wheat, gluten and gliadin).

A részvétel fő kizáró okai

  • Pregnancy
  • Alcohol or drug abuse
  • Helicobacter pylori or other bacterial or parasitic infections
  • Chronic inflammatory bowel disease, other digestive, nervous system, major psychiatric or immune diseases, or conditions limiting physical activity
  • Cancer, or ongoing chemotherapy or radiotherapy

A regiszter feltételei, szó szerint

Mind a 12 feltétel megnézéseKevesebb

Ki vehet részt

  • age >18 and <65 years
  • negativity of class A (IgA) and G (IgG) immunoglobulin (Ig) anti-deamidated gliadin (anti-DGP); negativity of IgA and IgG anti-tissue transglutaminase (anti-tTG) and anti-endomysial antibodies (EMA)
  • absence of intestinal villous atrophy, documented in all patients carrying the DQ2 and/or DQ8 human leukocyte antigen haplotypes (therefore regardless of the negativity of celiac disease-specific serum antibodies)
  • absence of wheat allergy (negative prick test and/or serum IgE measurement specific to wheat, gluten and gliadin)

Ki nem vehet részt

  • alcohol and/or drugs abuse
  • patients undergoing chemotherapy and/or radiotherapy
  • Helicobacter pylori and other bacterial and/or parasitic infections
  • diagnosis of chronic inflammatory intestinal diseases and other organic pathologies affecting the digestive system (for example, serious liver diseases), nervous system diseases, major psychiatric disorders, immunological deficits and impairments that limit physical activity
  • cancer
  • age <18 and >65 years
  • self-exclusion of gluten/wheat from the diet and refusal to reintroduce it, for diagnostic purposes, before entering the study
  • pregnancy

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 65 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Patients suffering from wheat-related troubles, in absence of celiac disease or wheat allergy diagnosis, can suffer from non-celiac wheat sensitivity (NCWS). This is characterized by both gastrointestinal (GI) and extra-intestinal symptoms, which improve with the elimination of wheat intake. To date no definitive explanation of pathogenetic mechanisms of NCWS has been proved, and, similarly, no specific non-invasive diagnostic biomarker has been recognized. A real need of strict adherence to wheat-free diet (WFD) in NCWS has never been demonstrated. In this context, research is actively trying to find wheat varieties with absent or low immune-reactivity to be used for the treatment of NCWS patients. Preliminary evidence supports the assumption that diploid wheat species, as Triticum monococcum (TM), compared to common ones (Triticum aestivum (TA), could possess a lower immunogenic potential in NCWS patients. The first objective of our project is to verify whether the use of a diploid wheat (TM), with a lower concentrations and bioactivity of Amylase-Trypsin-Inhibitors (ATIs) and with gliadin proteins with a better digestibility, compared to a hexaploid one (TA) could improve both symptoms and quality of life (QoL) of NCWS subjects. The second objective is the identification of non-invasive serological biomarkers for NCWS diagnosis. The third objective is to identify T cell lymphocytes able to recognize cognate peptides from wheat proteins to better classify and monitor patients affected by NCWS. To achieve these results we planned a prospective, double-blind clinical trial with crossover, in which patients already diagnosed with NCWS (according to international criteria and with a double-blind placebo-controlled wheat challenge), following a strict WFD, will be exposed in double-blind to both TM and TA. All the patients will be evaluated clinically at the different timepoints with validated scales to assess tolerability of TM. Moreover, their intestinal permeability, immunological activation and gut microbiota patterns will be studied by both in vitro and in vivo techniques. Finally, a randomly chosen subset of patients will be studied through single cell transcriptome and T-cell receptor (TCR) sequencing on rectoscopy biopsy specimens to identify, T cell lymphocytes able to recognize cognate peptides from wheat proteins.

A vizsgálat 2 csoportja

  • NCWS Packets A-BA vizsgált kezelés

    NCWS patients will undergo a Double-Blind Wheat Challenge DBWC with an ancient diploid wheat (TM) or a modern hexaploid wheat (TA). This DBWC will be performed with flour packets coded A or B, each containing respectively one of the wheat varieties. Packets A or B will be given for 1 week and then, after 1 week of washout (or until patients report complete well-being), the patients will receive the other packets for another 1 week (cross-over design).

    Kezelés: Administration of Triticum Monococcum flour és Administration of Triticum Aestivum flour

  • NCWS Packets B-AA vizsgált kezelés

    NCWS patients will undergo a Double-Blind Wheat Challenge DBWC with an ancient diploid wheat (TM) or a modern hexaploid wheat (TA). This DBWC will be performed with flour packets coded A or B, each containing respectively one of the wheat varieties. Packets A or B will be given for 1 week and then, after 1 week of washout (or until patients report complete well-being), the patients will receive the other packets for another 1 week (cross-over design).

    Kezelés: Administration of Triticum Monococcum flour és Administration of Triticum Aestivum flour

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Tolerability of an Ancient Grain in Patients With Non-Celiac Wheat Sensitivity. A Clinical Study and a Search for Diagnostic Biomarkers.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT06191432: ki vehet részt
A regiszteradat frissítve
2026. január 12.